Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;27(2):1005-1009.
doi: 10.1111/dom.16076. Epub 2024 Nov 20.

Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials

Giovanni Antonio Silverii  1 , Laura Pala  2 , Barbara Cresci  2 , Edoardo Mannucci  1
Affiliations

Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials

Giovanni Antonio Silverii et al. Diabetes Obes Metab. 2025 Feb.
No abstract available

Keywords: GLP‐1 analogue; antidiabetic drug; antiobesity drug; clinical trial.

PubMed Disclaimer

Conflict of interest statement

GAS, LP and BC have no conflicts of interest to declare. The unit directed by EM has received research grants from Abbott, Eli‐Lilly and Novo Nordisk, outside the submitted work. EM has received consultancy fees from Dexcom and Sanofi and speaking fees from Astra Zeneca, Boehringer‐Ingelheim, Eli‐Lilly and Novo Nordisk, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Incidence of ischemic optic neuropathy in patients with GLP1‐RA and comparators. GLP1‐RA, glucagon‐like peptide 1 receptor agonists; M‐H, Mantel–Haenszel.
See this image and copyright information in PMC

References

    1. Lingvay I, Agarwal S. A revolution in obesity treatment. Nat Med. 2023;29(10):2406‐2408. doi:10.1038/s41591-023-02538-7 - DOI - PubMed
    1. Lincoff AM, Brown‐Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221‐2232. doi:10.1056/NEJMoa2307563 - DOI - PubMed
    1. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069‐1084. doi:10.1056/NEJMoa2306963 - DOI - PubMed
    1. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity‐related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394‐1407. doi:10.1056/NEJMoa2313917 - DOI - PubMed
    1. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109‐121. doi:10.1056/NEJMoa2403347 - DOI - PubMed

LinkOut - more resources